Reevaluating ADHD and its First-Line Treatment: Insights from DSM-5-TR and Modern Approaches

Area of Science:

• Psychiatry and Neurodevelopmental Disorders
• Medical Discourse Analysis
• Neurodiversity Studies

Background:

• The biomedical model of Attention Deficit Hyperactivity Disorder (ADHD) is increasingly scrutinized.
• Previous diagnostic criteria and treatment paradigms are being re-examined in light of new evidence.
• Concerns exist regarding the neurobiological basis and pharmaceutical management of ADHD.

Purpose of the Study:

• To critically analyze the biomedical discourse surrounding ADHD, particularly its classification and treatment.
• To evaluate the scientific basis for ADHD as a neurobiological disorder.
• To explore alternative perspectives, such as the neurodiversity model, for understanding ADHD.

Main Methods:

• Analysis of the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision (DSM-5-TR).
• Review of authoritative sources including previous DSM editions, consensus statements, and FDA communications.
• Examination of neuroimaging literature and empirical evidence related to ADHD.
• Application of evolutionary principles and historical context to ADHD discourse.

Main Results:

• The DSM-5-TR acknowledges the absence of diagnostic biological markers for ADHD.
• Meta-analyses of neuroimaging studies show no significant differences between individuals with and without ADHD.
• The FDA has strengthened warnings on prescription stimulants due to risks of misuse, abuse, addiction, and overdose.
• The article challenges the neurobiological basis of ADHD and questions the routine use of stimulant medications.

Conclusions:

• Current evidence does not support ADHD as a distinct neurobiological disorder.
• The risks associated with stimulant medications necessitate a re-evaluation of first-line ADHD treatments.
• ADHD may be better understood as a socio-philosophical category of 'conflicts between the individual and society,' aligning with the neurodiversity paradigm.